美股新聞 標題聯播 · 近 24 小時 242 則 · 24 個來源 · 最新 9/20 09:06
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · RVTY近 30 天 11 則 · 第 1 / 1 頁
- Strength Seen in Revvity (RVTY): Can Its 9.1% Jump Turn into More Strength?
- Q2 Rundown: Revvity (NYSE:RVTY) Vs Other Research Tools & Consumables Stocks
- VNRX: VolitionRx Prepays Outstanding Balance on the $7,500,000 Lind Senior Secured Convertible Promissory Note Dated May 20, 2025. Review of Papers, Posters, and Videos Released in Mid-2026. Sysmex Collaboration is the 3rd Recent Agreement in the Human Space.
- Revvity to Acquire Human Cell Design to Boost Metabolic Discovery
- Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery
- Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich?
- Global Multiplex Assays Market 2026 Edition - Consumables Dominate Multiplex Assays with 68% Market Share
- Revvity (RVTY) Stock Looks Fair On Cash Flow Yet Pricey On Earnings
- What Makes Revvity (RVTY) a New Buy Stock
- Revvity Faces Growth Challenges Amid Rising Competition, RBC Says
- Is the Options Market Predicting a Spike in Revvity Stock?
- Revvity Launches SuperFlex Prenatal Screening System for Smaller Labs
- The Top 5 Analyst Questions From Revvity’s Q2 Earnings Call
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。